GlobeNewswire Clinical StudiesOriginal article
Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34
Phase 1positiveTT-P34Positive
AI Analysis
Summary
Teitur Trophics announced successful Phase I clinical trial results for TT-P34, a first-in-class peptide therapeutic for Parkinson's disease.
Clinical Trial Data
Phase
Phase I
Primary Endpoint
Met
Outcome Details
Successful Phase I clinical trial results
Importance:5/10
Sentiment:
0.75
Parkinson's diseasepeptidefirst-in-classPhase 1 data
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 10, 2026 7:30 AM